Podcasts about copd

Discover the profound impact of Vitamin K1 on respiratory health in this breakdown of a decade-long study involving over 179,000 adults. While Vitamin K2 often steals the spotlight for bone and heart health, new data suggests K1 is the "ruler of the realm" when it comes to protecting the lungs and reducing the risk of chronic lung disease (COPD).In this episode, we explore the science behind the "Matrix GLA Protein" (MGP), how leafy greens like kale and spinach act as "Green Power" for your lungs' elasticity, and why current daily recommendations for Vitamin K might be falling short of optimal levels.Key Takeaways:The K1 vs. K2 Difference: Why K1 is essential for lung function and fiber elasticity.COPD Risk Reduction: A 16% lower risk found in those with the highest K1 intake.The "Trampoline" Effect: Visualizing how K1 protects the elastic structures that help you breathe.Practical Serving Sizes: How much cooked kale or spinach is needed to reach optimal levels.Timestamps0:00 The Profound Impact of Vitamin K1 vs K2 on Lungs0:36 Analyzing the Study Data: Q1 vs Q5 Intakes 1:13 Is the 70mcg RDI Optimal or Just a Minimum? 1:44 Lung Function and the Difference in Breathing Depth 2:15 The Matrix GLA Protein (MGP): Protecting Lung Elasticity2:30 Green Power: Tracking 179,000 Adults Over a Decade 3:14 16% Reduction in COPD Risk Explained3:55 How K1 Activates Protective Elastic Fibers 4:36 Visual Comparison: Healthy vs. Stiff Lung Function5:01 Detailed Look at Matrix GLA Protein Activation 5:28 Raw vs. Cooked Kale: Maximizing Your K1 Intake 5:56 Study Validation: Hazard Ratios and Confidence Intervals 6:16 K1 for Lungs and Clotting vs. K2 for Bones and Arteries6:56 Addressing the "Healthy Volunteer Effect" in the UK Biobank 7:29 Terminology Glossary and Final Summary 8:10 Are Current RDI Guidelines Too Low for Respiratory Health?#VitaminK1 #COPD #LungHealth #MatrixGlaProtein #STEM #NutritionScience #RespiratoryWellness #HealthyAging #Emphysema #TheCatalystFormal Citation (AMA Style)Li C, Pokharel P, Sim M, et al. Dietary vitamin K intakes, chronic obstructive pulmonary disease, adult asthma, and lung function: a prospective cohort study in the UK Biobank. Am J Clin Nutr. 2026;123(101324):1-12. doi:10.1016/j.ajcnut.2026.101324Medical & Legal DisclaimerDisclaimer: The information provided here is for educational and informational purposes only and is not intended as medical advice. Dietary changes, particularly those involving vitamin K intake, can interact significantly with anticoagulant medications (blood thinners). Always consult with your physician or a qualified healthcare provider regarding a medical condition, diet, or treatment. The narrator and analysis team (The Catalyst) do not monetize this information and provide it as a public service.vitamin K1, K1 VS. COPD, lung blueprint, K1 lung health, COPD prevention, vitamin K-dependent proteins, Matrix Gla Protein, MGP, lung volume, pulmonary function, FEV1, FVC, spirometry, UK Biobank, dietary phylloquinone, green leafy vegetables, lung structure preservation, elastic fiber degradation, emphysema, nutritional epidemiology, chronic respiratory disease, respiratory wellness, Catalyst analysis, Ralph Turchiano, high-energy science, STEM education, non-monetized data.

Department Chair of Emergency Medicine at Cook County Health Dr. Trevor Lewis joins the Lisa Dent Show to discuss how the poor air quality will affect people’s health and who’s most at risk of falling ill given the current conditions. He advises asthmatics and COPD patients to either use their inhaler or seek immediate medical […]

Curious how AI can query your enterprise data without moving it or making things up? AWS and Teradata break down a trustworthy analyst agent built for real production use.Topics Include:Neha Wadhera (AWS) introduces Trinath Yarlagadda and the Teradata Analyst AgentEnterprise AI data prep is costly, stalling most orgs at experimentationAgent answers plain-English questions via traceable SQL, zero data movementBarrier removal drives 3.7x ROI and 40% productivity gainsHealthcare demo setup: hospital COPD readmissions, ~$10K cost per incidentFour design principles: traceability, no data movement, deterministic-first, governance as codeMain orchestrator agent plans, writes SQL, calls Teradata MCP serverComplex questions escalate to a context-isolated data scientist agentBuilt on Claude Agent SDK, running Bedrock Claude Sonnet/Haiku/OpusLive demo: COPD readmission rates explored through iterative agent reasoningDelegation demo: data scientist agent runs in-database analysis, surfaces factorsPre/post tool hooks log every step and cost to CloudWatchAgent hosted on Amazon Bedrock AgentCore, fully serverless and scalableAgentCore delivers runtime, memory, identity, and observability out of the boxLessons learned: guardrails first, deterministic ops, multi-agent registry, ongoing evaluationParticipants:Trinath Yarlagadda – Principal Solution Architect – Agentic AI, TeradataNeha Wadhera – Sr Solutions Architect, Amazon Web Services See how Amazon Web Services gives you the freedom to migrate, innovate, and scale your software company at https://aws.amazon.com/isv/

Send us Fan Mail#eveningprayer #pray #jesus #god #christianprayer #HolySpirit Evening Prayer (Thank You LORD; Forgiveness; Pneumonia; COPD; Diabetes; Malaria; Praise)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

Are your blood markers telling you and your doctor the whole story? Chronic inflammation is the silent driver behind nearly every major disease, and the good news is that your lifestyle choices decide the outcome. Don't wait for a life altering diagnosis to take action.In this episode of Salad With a Side of Fries, host Jenn Trepeck breaks down how blood markers move, how preventable diseases develop, and why epigenetics means your genes are not your fate. If you have ever felt like your health was out of your hands, this episode will change the way you think about your daily choices.What You Will Learn in This Episode:✅ Why chronic inflammation is considered the root cause of virtually every major illness and how oxidative stress accelerates disease progression in the body.✅ How epigenetics reveals that your lifestyle choices, not just your genetics, impact disease-related genes.✅ What specific blood markers to track for heart disease, type 2 diabetes, liver disease, and kidney disease, and realistic timelines for improving them.✅ How to advocate for yourself in a medical system still rooted in a prescription-first approach, and how to ask your doctor for the time and space to make disease prevention changes first.The Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS:00:00 Preventable diseases don't have to be your story and what blood markers can and cannot tell you05:55 The most common diseases: heart disease, type 2 diabetes, and cancer and how they are linked to lifestyle choices06:46 Epigenetics explained: how your daily habits turn disease risk genes up or down17:21 Lifestyle choices, from gut health to the brain to the endocrine system, impact every organ system20:10 Oxidative stress and free radicals explained: the science behind chronic disease25:01 Lifestyle choices that support overall health rather than disease and healthcare 3.0, being your own advocate32:12 Discussion of food with no labels; vegetables, fruit and lean meat36:19 Movement as disease prevention: why sitting all day quietly drives chronic illness more than we realize41:06 Longevity, community, connection, sleep, and stress management as overlooked pillars of health42:05 Blood marker timelines: how fast insulin, A1C, cholesterol, and blood pressure respond to lifestyle changesKEY TAKEAWAYS:

In this episode of the Industry Matters Respiratory Edition, recorded live at VGM Heartland 2026, host Boone Lockard, VP of HME, Respiratory, and Wellness at VGM, sits down with Dr. Colleen Lance, Chief Medical Officer at React Health, and Bill Shoop, CEO of React Health, to unpack the seismic shifts in the NIV and ventilation market following the release of the new National Coverage Determination (NCD) for COPD. They discuss what changed in policy, how providers have adapted (or struggled), the role of CO2 requirements and adherence monitoring, best practices for patient care, and what the future of NIV looks like across the full spectrum of chronic respiratory disease. Whether you're an HME provider, prescriber, or manufacturer, this conversation offers practical insights on partnership, education, and navigating change in a rapidly evolving regulatory landscape.Watch the video version on YouTube: https://www.youtube.com/watch?v=1sKodXo-J5k

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/learn/course/recent-research-into-biologics-in-asthma-10830Program DescriptionThis podcast activity provides an in-depth review of several recent trials in severe asthma management, highlighting the ongoing shift in asthma precision medicine towards identifying the right patients for the right treatments. Clinicians will examine clinical data from the NIMBLE trial (depemokimab), alongside the WAYFINDER trial (tezepelumab), as well ZEPHYR 5 (benralizumab), REMOMEPO (mepolizumab), VESTIGE (dupilumab) and VALLIANT (verekitug). This activity will grant clinicians critical insights to move beyond simple exacerbation reduction and precisely align advanced biologic therapies with the underlying cellular biology driving each patient's symptoms.Educational ObjectiveAt the conclusion of this activity, participants should be better able to:Review recent updates in the asthma literature, including recent guideline revisions and evolving clinical trial data for newer biologic therapies.Accredited ProvidersThe National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).FacultyCedric Rutland, BS, MD, FCCPVolunteer FacultyUniversity of CaliforniaPulmonary Critical Care Internal Medicine, ProducerRutland Medical GroupNewport Critical Care PhysiciansLake Forest, CADr. Rutland has disclosed the following financial relationships:Consultant: Sanofi (asthma, diabetes, NP, RSV, AD), Boehringer Ingelheim (IPF, PPF), Regeneron (asthma, diabetes, NP, RSV, AD), Chiesi (asthma), Baxter (bronchiectasis), Insmed (bronchiectasis), AstraZeneca (asthma, cough)Advisor/Advisory Board: Sanofi (asthma, AD, NP), Regeneron (asthma, AD), Chiesi (asthma), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough)Speaker: Sanofi (asthma, NP, AD, AFRS, urticaria, EoE), Regeneron (asthma, NP, AD, AFRS, urticaria, EoE), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough), Chiesi (asthma), Baxter (bronchiectasis)These relationships have ended within last 24 months:Consultant: GSK (asthma, cough, RSV)Advisor/Advisory Board: GSK (asthma, cough, RSV)Speaker: GSK (asthma, cough, RSV)Diego J. Maselli, MD, FCCP, ATSFProfessor and ChiefDivision of Pulmonary Diseases & Critical CareUT Health at San AntonioDirector, Respiratory Care, University Health SystemDirector, Severe Asthma Program, University Health SystemSan Antonio, TXDr. Maselli has disclosed the following financial relationships:Consultant: AstraZeneca (asthma, COPD), Sanofi/Regeneron (asthma, COPD), GSK ( asthma, COPD), Amgen (asthma, COPD), Insmed (bronchiectasis)Speaker: GSK (asthma, COPD), AstraZeneca (asthma, COPD), Amgen (asthma, COPD), Sanofi/Regeneron (asthma, COPD)All of the relevant financial relationships listed for these individuals have been mitigated.Nurse Planner and Peer ReviewerMarjorie Crabtree, DNP, FNP, ANPHaymarket Medical EducationSteering CommitteeNurse Practitioner Healthcare FoundationAccredited Provider Program DirectorBellevue, WADr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.Accredited Provider DisclosureNACE staff has no relevant financial relationships to disclose.Intended AudiencePulmonology, allergy/immunology, and critical care clinicians (physicians, nurse practitioners, and physician associates), as well as primary care and geriatric medicine clinicians caring for patients with asthma.Commercial SupportersThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

SUMMARY Arundhati Parmar speaks with Jill Schwartz-Chevlin, Chief Medical Officer at Vinca, about the evolution of palliative care from a hospital-based, end-of-life service to a community and home-based model for patients living with serious illness. Jill explains how Vinca grew from an advanced care planning platform into a value-based palliative care company serving patients across five states, primarily through Medicaid and Medicare Advantage plans. The conversation covers the critical distinction between palliative care and hospice, the cost savings data that health plans are paying attention to, and what it will take for Medicare to finally build a sustainable reimbursement model for the specialty. KEY TAKEAWAYS Palliative care is not hospice. It is symptom management and whole-person support for patients still pursuing active treatment for serious illness, including cancer, COPD, and advanced heart failure. More than 75% of hospitals now have palliative care teams, but their positioning around end-of-life discussions has created a widespread misconception that palliative care equals dying. Home-based palliative care through Vinca produces a 42% reduction in ER admissions and a 53% reduction in hospitalizations. Only three states (California, Hawaii, and New Jersey) have established a Medicaid benefit specifically for palliative care. Traditional Medicare offers no such benefit. The current fee-for-service model for palliative care is not sustainable. Most palliative care programs linked to hospices survive only because the hospice subsidizes them. KEYWORDS palliative care at home, home-based palliative care, serious illness management, palliative care vs hospice, Vinca health, value-based palliative care, Medicaid palliative care benefit, Medicare Advantage palliative care, community palliative care, advanced care planning, hospice length of stay, ER reduction palliative care, whole-person care, serious illness, home health palliative care, CMO interview healthcare, palliative care reimbursement, MedCity Pivot podcast Links and resources  Connect with Arundhati Parmar  aparmar@medcitynews.com  Arundhati Parmar (@aparmarbb) on X MedCity News EPISODE HIGHLIGHTS [00:02:04 – 00:02:36]  Jill defines palliative care: symptom relief, patient wishes, team-based approach [00:03:11 – 00:03:46]  Why hospital palliative care teams created the end-of-life association [00:06:13 – 00:07:06]  Vinca's 15-year journey from advanced care planning to full palliative care services [00:11:43 – 00:12:07]  The data: 42% ER reduction, 53% hospitalization reduction [00:12:52 – 00:13:31]  Patient story: metastatic pancreatic cancer, golf one month ago, ER the next [00:18:47 – 00:19:29]  Jill clarifies the hospice misconception: 90% of hospice care happens at home [00:22:50 – 00:24:10]  Why Medicare's fee-for-service model for palliative care is failing and what should replace it

Hot, humid summer weather can make breathing more difficult—especially for people living with asthma or COPD. In this episode, Dr. Aliaksandr Ramaniuk,Summa Health pulmonologist explains what happens in your lungs during extreme heat and shares practical tips to help you stay safe, recognize early warning signs, and prevent flare-ups. Learn how simple steps—like checking air quality, staying hydrated, and planning ahead—can help you enjoy summer with confidence.  Schedule an Appointment with Dr. Ramaniuk 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, where significant scientific advancements, regulatory shifts, and strategic business maneuvers are reshaping patient care and therapeutic approaches. A pivotal moment recently unfolded with Ipsen's acquisition of Kartos Therapeutics for up to $1.75 billion. This strategic move adds navtemadlin, a promising myelofibrosis candidate, to Ipsen's oncology pipeline. Navtemadlin is a small molecule inhibitor targeting MDM2, a crucial regulator of the tumor suppressor p53. This acquisition reflects a strategic emphasis on expanding therapeutic options in hematologic oncology, aiming to improve outcomes for patients with myelofibrosis—a rare and debilitating bone marrow disorder. In regulatory advancements, Viridian Therapeutics achieved a significant milestone with FDA approval of Lumvoa (veligrotug-vvze) for treating thyroid eye disease across both active and chronic stages. This monoclonal antibody targets IGF-1R, addressing an unmet need in autoimmune conditions by potentially altering disease progression and improving patient quality of life. Concurrently, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) secured EU approval for HER2-positive metastatic solid tumors after successful Phase 2 trials. Enhertu's role as an antibody-drug conjugate highlights a breakthrough in targeting cancer cells more precisely while sparing healthy tissues, underscoring the growing importance of personalized medicine in oncology. The clinical trial landscape saw pivotal results with AstraZeneca's efzimfotase alfa demonstrating efficacy in Phase 3 trials for hypophosphatasia—a rare bone disease characterized by defective bone mineralization due to enzyme deficiencies. This protein therapy aims to replace deficient alkaline phosphatase enzymes, offering hope for improved skeletal outcomes in affected children. Furthermore, BridgeBio Pharma's infigratinib showed promise in Phase 3 trials for treating achondroplasia by demonstrating significant growth improvements. As a fibroblast growth factor receptor (FGFR) inhibitor, it underscores the potential of targeted therapies in addressing genetic disorders. On the business development front, Zymeworks' acquisition of Theravance for $929 million adds the COPD drug Yupelri to its portfolio alongside lucrative royalty arrangements. Yupelri is a long-acting muscarinic antagonist (LAMA) that offers once-daily bronchodilation for COPD patients. This strategic move bolsters Zymeworks' respiratory franchise and highlights the ongoing consolidation trend in the industry as companies seek growth through diversification and enhanced therapeutic offerings. In parallel, Talawar Therapeutics is planning a $285 million SPAC merger to advance its bispecific antibody for eczema treatment. Similarly, Lycia Therapeutics raised $75 million in Series D funding to progress its extracellular protein degrader pipeline aimed at autoimmune diseases. These investments signal robust interest in novel modalities such as bispecific antibodies and targeted protein degradation technologies that promise new therapeutic avenues. However, not all news was positive. The FDA rejected Sobi's NASP (pegadricase) application due to manufacturing issues, highlighting ongoing challenges firms face in meeting regulatory standards for complex biologics. Additionally, Evommune's Evo756 failed its primary endpoint in Phase 2b trials for chronic spontaneous urticaria, illustrating the high-risk nature of drug development. Looking at the broader industry trends, Roche's launch of Axelios 1 represents a strategic push into the gene sequencing arena, directly challenging Illumina's market dominance. As precision medicine continues to gain traction, advancements in gene sequencing technologies are likely to play an instrumental role in personalized medicine strategies, offering more tailored treatment options based on genetic profiles. Finally, we see significant shifts driven by recent regulatory changes and scientific breakthroughs across the sector. The FDA's revised stance on rare disease drug approval criteria could expedite processes for companies like Skyhawk Therapeutics and Biohaven, providing new opportunities to bring treatments to market more swiftly. These regulatory adjustments reflect an evolving landscape where innovation is poised to meet unmet medical needs more efficiently. In conclusion, these developments underscore a dynamic pharmaceutical and biotech landscape characterized by strategic acquisitions, regulatory successes, and scientific advancements aimed at addressing complex diseases with innovative therapies. As these sectors continue to evolve, stakeholders must navigate a complex interplay of technological advancements, regulatory scrutiny, and competitive pressures to drive meaningful advancements in healthcare outcomes. Stay tuned with Pharma Daily as we continue to explore these significant shifts shaping the future of healthcare and drug development. Thank you for joining us today as we unpack these pivotal stories impacting our industry.Support the show

In this episode of the UConn Internal Medicine Podcast Series, we discuss the evolving role of biologic therapies in asthma and COPD. We review how biologics target Type 2 inflammation, how to identify patients with severe asthma who may benefit from therapy, and how biomarkers such as blood eosinophils, FeNO, IgE, and allergic sensitization guide treatment selection.We also explore newly approved biologics for COPD, practical differences between available agents, expected benefits, steroid-sparing effects, safety considerations, pregnancy counseling, helminth screening, and real-world barriers such as cost and insurance approval.This episode is designed for internal medicine trainees and clinicians looking for a practical framework to understand when to consider biologics, how to choose the right agent, and what to monitor after starting therapy.Hosts:Dr. Hossam Albeyoumi Mohammed, and Dr. Simran Umra, Chief Medicine Residents, UConn.Dr. Alisa Pasichnik, and Dr. Caroline McCauley, 3rd year medicine residents, UConn.Guests:Dr. Ethan Bernstein, Associate Program Director of the Department of Pulmonary and Critical Care Medicine, UConn.Dr. Angela Quental, incoming Assistant Professor in the Department of Pulmonary and Critical care medicine, UConn.Edited by:Dr. Hossam Albeyoumi Mohammed, Chief Medicine Resident, UConn.Music:LoFi Girl by Snoozy Beats | Free Music Archive | Livense: CC BY.

TR is an 88-year-old man who is disabled and in chronic pain from spinal stenosis and knee osteoarthritis. He has multiple other medical issues, including coronary artery disease and COPD.He has been through years of treatment for his knees and back, including physical therapy, multiple joint injections, and an in-office procedure for spinal stenosis. He has been on multiple regimens of oral pain medications. He is not interested in surgery (and probably would not be considered a reasonable candidate if he were).He comes to a visit and asks what can be done.Sensible Medicine is a reader-supported Substack. If you appreciate our work, consider becoming a free or paid subscriber.We are taught never to say, “There is nothing I can do for you.” We may be out of surgical or medical options, but we can always continue to care for and support our patients. This is not part of the Hippocratic Oath, but it is so integral to our training that one might think it belongs there.There are good reasons to caution doctors from saying some version of, “I am sorry, I don't think there is anything more I can do for you.” It is true that in 21st-century medicine, the act of caring for patients has been so trivialized that we need to remind ourselves that caring is not just a last resort but our first responsibility.Hope in the face of illness is exceedingly valuable. Robbing this hope is not only cruel, but probably bad for the health of patients.Then there is the truth that when one doctor has nothing left to offer, medicine often still has more to offer. I am still haunted by at least one case when I mistook my lack of knowledge for a shortcoming in the field.A doctor saying he has nothing left to offer may be taking the easy way out. Further research or a considered referral often suggests effective treatments, if not cures. There is always a risk that when we say, “We can't help,” we are wrong.All this being true, I don't think we admit that there is nothing left to be done often enough. The Modern Hippocratic Oath does include the line:I will not be ashamed to say “I know not”, nor will I fail to call in my colleagues when the skills of another are needed for a patient's recovery.Is it that much of a stretch to imagine the oath saying:I will not be ashamed to say “I have nothing left to offer beyond my ongoing care and commitment”, nor will I call in my colleagues, knowing they have nothing to offer beyond protecting me from admitting medicine's limitations.We no longer conceal bad diagnoses from patients; we consider this unethical. It is time that we consider it unethical to conceal that we have nothing to offer beyond palliation.It is hard to tell patients that the best we can do is control pain, especially when we have been trained not to. It takes work to be sure that neither you nor your colleagues have something to offer beyond a hamster wheel of care to provide hope but nothing more. It also takes some guts; we can never be 100% sure that nobody has anything to offer.Yet there are downsides to never saying we are done. Many patients accept that further care is futile, not after an honest conversation, but after being worn down by my endless visits, treatments, and promises that lead nowhere. All the while, time and money are wasted; time and money that could be better spent on life. The useless medical care leaves patients and their families increasingly frustrated by a medical system that refuses to be honest and caring.There are patients who welcome an honest assessment of their options and shift their focus to living with their disease and disability. There are also patients who do not. I've had patients fire me for saying there was nothing to do. They left me to get on that hamster wheel of care. This decision did not make them better, but maybe it made them happier and more ready to accept the inevitable. Eventually.TR calls now and then and comes to see me every three or four months. He tells me about his symptoms and the things he wishes he could do. I tell him there are things he could try and people he could see, but I let him know I don't think any of these options would be productive. He tells me he's not interested. I advise him to push up on his pain medications and to pretreat his symptoms; I know he will not take this advice. I know we will repeat this visit in the future; I actually hope we will, for years. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

On today's episode of Beating Cancer Daily, Saranne welcomes Jacqui Bryan, a functional medicine expert, to explore the often-overlooked challenge of muscle loss and its impact on individuals facing cancer, aging, and chronic illness. The conversation centers on sarcopenia, or age-related muscle decline, highlighting not only its insidious onset but also practical strategies for prevention and reversal at any age. As a 33-year Stage IV cancer survivor, Saranne discusses her personal experiences with muscle and bone loss during treatment, while Jacqui shares actionable advice for maintaining muscle health, even for those who are bedridden or recovering from cancer therapy. Jacqui Bryan is a certified nutrition specialist, whole health educator, health coach, and registered nurse. Having survived cancer herself, Jacqui brings firsthand experience and clinical expertise to her holistic approach. Her deep understanding of nutrition, movement, and the specific needs of cancer patients has helped countless individuals regain strength and reclaim their vitality."Sarcopenia is the slow erosion of your body's engine... It's almost entirely preventable and partially reversible at any age." ~Jacqui Bryan Today on Beating Cancer Daily:·     Sarcopenia, or age-related muscle loss, is a serious yet often underdiagnosed condition that can be both prevented and partially reversed at any age.·     Cancer patients, survivors, and anyone age 30 or older, especially those who are sedentary, are at increased risk of significant muscle loss.·     Muscle tissue is a metabolic organ crucial for blood sugar regulation, immune function, and maintaining independence as we age.·     Resistance training two to four times per week is the most effective strategy for preserving and building muscle, even well into your 80s and 90s.·     Adequate, high-quality protein (around 25-30 grams per meal) and nutrients such as vitamin D and omega-3 fatty acids are essential for maintaining muscle mass.·     Postmenopausal women and individuals with chronic conditions such as diabetes, heart failure, COPD, and chronic kidney disease face accelerated risks and should be especially vigilant.·     Chronic stress, poor sleep, and restrictive diets can all accelerate muscle loss; stress management and sleep hygiene are critical components of muscle preservation.·     For those struggling with muscle loss after treatments, especially Stage IV cancer survivors and the bedridden, asking healthcare providers about physical therapy and working with dietitians can make a significant difference. Contact Jacqui:jacquibryan.com 2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_SuggestionsTo sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

In this heartfelt and deeply honest episode, we explore the intersection of entrepreneurship, motherhood, and the raw reality of grief. We sit down with Colleen to discuss the journey of losing a father who struggled with lung cancer and COPD, the complexities of "preventable" loss, and the challenge of maintaining your spark while navigating the darkest seasons of life.In this episode, we discuss:The Reality of "The Dash": Reflecting on life, love, and what it truly means to live between the dates on our tombstones.Grief and Entrepreneurship: How to keep your business moving, launch courses, and serve clients while processing profound personal loss and life-altering tragedy.The "Strong One" Syndrome: Managing the expectations we put on ourselves to be the resilient ones for our families, our children, and our teams while internally falling apart.Signs and Surrender: Finding small, beautiful moments of connection and signs from loved ones after they pass.The Process of Integration: Why "healing" isn't about returning to who you were before, but integrating your grief into the new version of yourself.Connect with our Guest:Instagram/LinkedIn/YouTube: @transcendingmindsConnect with Nicole:

In this week's Real Take, Tara Rafter reflects on her mother's final days living with COPD​ and the heartbreak of saying goodbye to the woman who had been her anchor throughout life.​If this excerpt resonates with you, I highly recommend listening to the full episode:Tara Rafter: Hypervigilance to Healing​Growing up in a home impacted by alcoholism and domestic violence, she learned from a young age how to navigate uncertainty. Despite the difficulties her family faced, she speaks with remarkable compassion about both of her parents, who died far too young.A​nd alongside her personal story, Tara brings the perspective of a Master Neuro Linguistic Programming Practitioner and Executive Coach.Listen to the full episode wherever you get your podcasts. Hosted on Acast. See acast.com/privacy for more information.

​Topics covered include:​ Alcoholism​, domestic violence​, hypervigilance​, compassion​, motherhood​, self-abandonment​, being a carer​, death and loss​, grief​, faith​, spirituality​, forgiveness​, love​, safety​, self-worth​, self-sabotage​, overwhelm​, healing​.This week I'm joined by Master Neuro Linguistic Programming Practitioner, Executive Coach and founder of The Navigation Coach, Tara Rafter.Tara lives in Mayo with her husband Kevin and their son Kai.In this deeply honest conversation, Tara shares the story of her childhood growing up in a home impacted by alcoholism and domestic violence. She speaks candidly about the hypervigilance she developed from a young age, the lasting impact those experiences had on her life, and the remarkable compassion she holds for her father despite the challenges her family faced.Tara's story is one of resilience, but also of love, forgiveness and understanding. She reflects on her relationship with both of her parents, who died far too young. Her father passed away at the age of 58, while her beloved mother​, who was her anchor throughout life​, lived with COPD for several years before she died.We also explore motherhood, self-abandonment, self-worth, self-sabotage, overwhelm​ and what it means to truly feel safe in yourself.Alongside the more difficult chapters, this conversation is full of warmth and humour. Tara talks about her love of music​ and heading off to gigs on her own, her deep faith and the practices that have helped her navigate life's challenges.You can connect with Tara here:Website: thenavigationcoach.comEmail: tara@thenavigationcoach.com Hosted on Acast. See acast.com/privacy for more information.

In this episode of the RCP Medicine Podcast, respiratory consultant and clinical lead for environmental sustainability Dr Thom Daniels joins host Dr David Charles to explore why air quality should be treated as a core clinical issue rather than a distant environmental concern. Drawing on landmark coroner's cases, including the deaths of Ella Adoo Kissi Debrah and Awaab Ishak, they examine how outdoor and indoor pollution contribute to asthma, COPD, cardiovascular disease, stroke, dementia and health inequalities across the life course. The discussion covers practical ways to ask about air quality in consultations, from unexplained coughs to secondary prevention clinics, and sets out simple, evidence informed advice clinicians can offer to patients. They also consider policy and global perspectives, racial and social justice dimensions, and how clinicians can support patients who feel fatalistic about the environment.Resources https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/a-breath-of-fresh-air-responding-to-the-health-challenges-of-modern-air-pollution/ https://www.rcp.ac.uk/news-and-media/news-and-opinion/air-pollution-linked-to-30-000-uk-deaths-in-2025-and-costs-the-economy-and-nhs-billions-warns-royal-college-of-physicians/https://www.rcp.ac.uk/media/5r2kmmi4/rcp-full-report-a-breath-of-fresh-air-responding-to-the-health-challenges-of-modern-air-pollution.pdfThe RCP's six-step programme for the new consultant | RCP Explore our CPD portfolio by your career stageEducation and professional developmentLeadership CPDTeach the teacherEducational supervisorSix-step programme RCP Social MediaInstagramLinkedInFacebookBlueskyMusic Ep 50 onward - Bensound.com  Ep 1 - 49 'Impressive Deals' - Nicolai Heidlas Any adverts within this podcast may use computer generated voices

Matthew "Oki" O'Connor is the CEO of Scientific Affairs at Cyclarity Therapeutics, a clinical-stage biotech building a new class of medicines designed not to slow the accumulation of vascular damage but to reverse it. Oki and Chris first crossed paths as postdocs at Lawrence Berkeley National Lab in the mid-2000s — Oki was in Irina Conboy's lab, not far from the late Judy Campisi's group, where Chris was then working on cellular senescence. After Berkeley, Oki spent nearly a decade running the research program at the SENS Research Foundation, the organization most identified with the "damage repair" framing of aging biology, before co-founding Cyclarity (then known as Underdog Pharmaceuticals) in 2019 to translate one of SENS's most drug-tractable ideas into an actual molecule.When Oki was last on the show in March of 2023 (Episode 36), Cyclarity was deep in IND-enabling work and its lead asset, UDP-003, had only ever seen the inside of a mouse artery. At the end of that conversation, Chris asked what Oki hoped to be discussing the next time he visited. He answered, bluntly, that he wanted to be presenting human data. Last month, at the AHA Vascular Discovery Sessions, Cyclarity reported the results of their first-in-human Phase 1 trial of UDP-003 — a designed cyclodextrin that selectively binds 7-ketocholesterol, the oxidized cholesterol species that drives foam cell formation and arterial plaque. He's back to discuss what the drug actually did when it went hunting for 7KC inside a living human being.In this episode, Chris and Oki cover the unmet need that lipid-lowering drugs — statins, PCSK9 inhibitors, the coming Lp(a) agents — still don't address: none of them remove the damage already sitting in an artery wall. Oki explains the basic chemistry of 7-ketocholesterol and why macrophages, lacking the machinery to recycle it, collapse into foam cells and seed the necrotic core of advanced plaque. They walk through the engineering of UDP-003 as a dimeric beta-cyclodextrin "double cone" tuned for a single oxidized cholesterol species, the design of the 72-volunteer Australian Phase 1, and the exploratory pharmacodynamic readout that has the field's attention: dose-dependent urinary excretion of 7KC, stoichiometric with drug, cleared within a day. The conversation then turns to the 150-patient Phase 2 plan in coronary artery disease patients with plaque imaging as the primary biological readout, the funding math that stands between Cyclarity and that trial, the platform's reach into NASH, vascular dementia, AMD, and aging itself, and how all of this descends from the SENS damage-repair philosophy that Oki has been carrying since LBL.The Finer Details:- Why current standard of care is not enough — statins, PCSK9 inhibitors, GLP-1s, and the soon-to-arrive Lp(a) lowering agents all act by slowing the accumulation of arterial damage, not by reversing what's already there; despite 30 years on the market, statins have never demonstrated an all-cause mortality benefit in a clinical trial, and even the best statin imaging data shows only 1–2% plaque volume regression at very high doses in a subset of patients- The scale of the problem — atherosclerosis is estimated to contribute to roughly 40% of all human deaths once heart attack, stroke, and a surprisingly large COPD contribution are risk-adjusted in, on top of an enormous morbidity tail that includes angina, peripheral artery disease (up to and including amputation), and a growing case for vascular dementia as an undercounted driver of cognitive decline- The biology of 7-ketocholesterol — when an oxygen free radical reacts with cholesterol, it preferentially attacks the 7 position, and a second oxidation step locks the molecule into 7KC, a stable toxic species cells were essentially never equipped to recycle; it builds up in long-lived cells like macrophages, eventually shutting down their ability to traffic lipids back to the liver via HDL and converting them into foam cells that seed soft plaque and, over years, the necrotic core of advanced lesions- The molecular design of UDP-003 — cyclodextrins are naturally occurring carbohydrate rings; the beta size fits half a cholesterol molecule, and Cyclarity's in silico work showed that two beta-cyclodextrins facing wide-side to wide-side form a "double cone" that can fully encapsulate a single cholesterol; engineered correctly, that wrapper can be made selective for 7KC over native membrane cholesterol, which is what gives the drug its therapeutic window- The Phase 1 trial design and result — a traditional 72-volunteer safety study in Australia, split between single ascending dose and multiple ascending dose arms, escalating up to six doses at what Cyclarity believes will be the efficacious level; no serious adverse events, no bioaccumulation, drug excreted essentially completely in the urine (as predicted preclinically), and — the headline exploratory endpoint — dose-dependent urinary 7-ketocholesterol appearing on the same timescale as the drug, consistent with one molecule of UDP-003 binding one molecule of 7KC and leaving the body together- What the urinary 7KC readout can and cannot tell you — the easiest 7KC to mobilize is the free pool in circulation, but there is not nearly enough of it floating in the bloodstream to account for what came out in urine, which means the drug is reaching deeper compartments; how much is coming from vessel wall plaque versus liver versus other peripheral tissues will require the imaging endpoints of Phase 2 to answer- The Phase 2 plan — 150 coronary artery disease patients (the coronary being, as Oki puts it, the artery most likely to kill you), with baseline plaque imaging, a year of dosing, and a repeat scan; safety and PK continue, inflammatory biomarkers come on, and plaque volume change is the prize — for context, a 1% change in plaque volume is associated with roughly a 20% change in next-year risk of heart attack or stroke- The funding math and the platform — Cyclarity has raised $33M to date and needs roughly $45M more to run the Phase 2, with Phase 3 cardiovascular outcomes trials running into the hundreds of millions and likely requiring a pharma partner; beyond atherosclerosis, 7KC is elevated in NASH livers, in Alzheimer's brains, and in the retinal cells that die in age-related macular degeneration, and the underlying chemistry — designed binders that drag a specific toxic molecule out of the body — is meant to generalize into a pipeline against other accumulated damage species, the direct intellectual descendant of the SENS damage-repair programQuotes:"Atherosclerosis, or the plaque that builds up in your blood vessels in your arteries, is estimated to cause approximately 40% of all human death.""When [the macrophage] eats up too much oxidized cholesterol, it just accumulates it… And that's when you get this transition to these kind of monster blob cells called foam cells.""One molecule of our drug is supposed to bind one molecule of 7-ketocholesterol and then go away and never be seen again. You excrete both of them together.""A 1% change in plaque volume is associated with a 20% risk in the next year of your probability of having a heart attack or a stroke.""You pick one target at a time, you do it well, and you take it all the way to the clinic and hopefully prove that you can actually cure patients, help them get better, help their plaque shrink away, and prove that this approach can work."Links:Cyclarity Therapeutics: https://cyclarity.com

Welcome to the Atomic Anesthesia podcast hosted by CRNA professor Dr. Rhea Temmermand and Co-Founder Sachi Lord. On this show, you'll hear clear, clinically grounded discussions designed for nurse anesthesia residents and CRNAs who want to feel more confident in complex pharmacology, physiology, and real-world anesthesia decision-making.Want more content like this? Become a member of our learning platform: http://atomicanesthesia.comIn this episode:Why COPD is more than a lung problem — how alveolar destruction, V/Q mismatch, and cor pulmonale connect at the bedsideHow to ventilate a COPD patient intraoperatively: I:E ratios, PEEP strategy, and avoiding auto-PEEPThe pharmacology of bronchodilators — LABAs, LAMAs, and inhaled corticosteroids — and which ones to continue on the day of surgeryAnesthetic agent selection for reactive airways: why volatile agents help, why nitrous oxide doesn't, and when to consider TIVAPostoperative priorities: extubation to NIV, oxygen titration in CO2 retainers, and preventing reintubation

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Discover how to tap into your body's ultimate internal repair system and unlock the hidden regenerative power of your own stem cells.In this episode of Modern Healthspan, we explore the extraordinary capability of the human body to heal itself from within. Stem cell scientist Christian Drapeau breaks down how our bone marrow acts as a continuous engine for cellular renewal, deploying stem cells to target, repair, and revitalize damaged tissues. While our natural baseline release shifts over time, groundbreaking clinical data reveals that we can actively encourage our body to release fresh waves of its own stem cells into circulation. We discuss a remarkable six-month human trial where daily stem cell mobilization successfully helped restore normal heart function in chronic heart failure patients. You will also learn practical protocols to optimize this internal repair system using fasting, blood flow support, and advanced recovery tools like PEMF to guide these powerful cells exactly where your body needs them most.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Christina Prevett shares a detailed case study of a COPD patient named Bob, demonstrating how HIIT training can improve functional capacity and oxygen efficiency in pulmonary rehabilitation. The discussion covers personalized exercise protocols, monitoring strategies, and the importance of adaptable training for chronic conditions.  

On this episode of Healthline 3, Nate Blanchard sits down with Dr. Jerry San Pedro to discuss how summer heat and humidity impact your lungs and overall health. From asthma and COPD to air quality and exercise, they break down why breathing gets harder in the heat—and what you can do about it.Plus, viewer call-ins cover real concerns about managing symptoms, staying hydrated, and knowing when to seek medical help.

What does it take to go from helping millions of people breathe easier to helping patients keep their legs?   Join The Heart of Innovation as Kym McNicholas talks with Sarvajna Dwivedi, Ph.D., entrepreneur, inventor, and CEO of AngioSafe, whose career has spanned some of the most challenging problems in medicine.   Sarvajna co-founded Pearl Therapeutics, a company focused on breakthrough respiratory therapies that was ultimately acquired by AstraZeneca for $1.15 billion. Along the way, he helped develop inhaled therapies and drug-device combinations designed to improve the lives of patients with asthma and COPD. (AngioSafe United States)   Today, his focus has shifted from the lungs to the arteries.   As CEO and co-founder of AngioSafe, Sarvajna is leading the development of the Santreva-ATK Endovascular Revascularization Catheter, a novel device designed to restore blood flow through some of the most challenging chronic total occlusions (CTOs) physicians encounter in patients with peripheral artery disease (PAD). The technology is designed to cross completely blocked arteries, compress plaque, create a new channel, and restore blood flow without relying on a guidewire or external power source. (Medical Economics)   In this episode, we discuss:   • How a pharmaceutical scientist became a medical device innovator   • The story behind Pearl Therapeutics and its $1.15 billion acquisition   • Why chronic total occlusions remain one of the biggest challenges in PAD treatment   • How AngioSafe's Santreva-ATK technology works   • What it means to restore blood flow through arteries that are 100% blocked   • The future of cardiovascular and vascular innovation   If you or someone you love has peripheral artery disease, diabetes, leg pain while walking, non-healing wounds, or has been told an artery is completely blocked, this is a conversation you won't want to miss.  

We are in the third week of our four-part series on the 5th-largest killer in America.  This week, we talk about the diagnostics that can help prevent Chronic Lower Respiratory Disease and the tests that can help provide a roadmap to actually reverse it.  In this episode, you'll learn:—How Asthma is the majority of CLRD cases, while COPD is the number one category of CLRD deaths.—Why the Spirometry Lung Function Test is the most important tool to diagnose the Lungs.  And why Dr. Prather does not charge for follow-up Spirometry tests for those with severe Lung problems. —What factors Dr. Prather looks for to determine when  a Chest X-Ray is needed or when CT imaging is required for a patient.  And the common calcification Dr. Prather sees on Chest X-Rays due to Indianapolis being the "Histoplasmosis Capitol of America". —The importance of Vitamin D testing for respiratory health and the role it played during COVID.  And why Dr. Prather believes CLRD could be lowered by 85% if people just keep their Vitamin D levels in proper range.—The importance of Vitamin A as the recommended treatment for Measles.  And the history behind Cod Liver Oil as a great supplement for kids.—The importance of a Pulse Oximeter to check Blood Oxygen levels as a standard screening for all patients. —How Hair Analysis has been an important key to the health of so many patients, such as identifying toxic heavy metals like Cadmium which cause long-term damage to the Lungs. —Why Dr. Prather believes Sputum Cultures are under-utilized. —How a Stool Kit plays an important role for Lung health by identifying leaky gut issues that lead to Food Allergies.  Plus, how Parasites are a big cause of severe childhood Asthma and adult-onset Asthma.—Why too LOW levels of Hydrochloric Acid "almost always kicks off allergies" and is the reason for GERD and heartburn.  And why Proton Pump Inhibitors like Pepcid actually make the problem worse by lowering the Hydrochloric Acid in your stomach even more.http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

Learn how COPD treatment is changing, including newer medications, ways to prevent flare-ups, affordability tips and questions to ask your pulmonologist. Featuring Dr. Kathryn Robinett, a pulmonary critical care physician at UMMC Midtown Center for Pulmonary Health.  For more information about Dr. Robinett 

Send us Fan MailMorning Prayer (Rejoice in LORD; Body of Christ; Blood Pressure; COPD; Mercy of God) #morningprayer #christianprayer #Jesus #HolySpirit #copd #joy #loveThank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

How deep you breathe is the number one indicator of how long you will live.  This week, we continue our four-part series on the 5th-largest killer in America.  In this episode, we talk about:—How the majority of people with Chronic Lower Respiratory Disease have Asthma, which can also lead to COPD.—Why quitting cigarette smoking is the most important treatment for your lungs.  And how Holistic Integration is able to help patients to quit smoking through Auriculotherapy, Acupuncture ,and Homeopathy.—The importance of proper deep, diaphragmatic breathing techniques to keep,your lungs healthy.  And why Dr. Prather believes this is the main reason that women develop Chronic Lower Respiratory Disease more than men. —The reason Dr. Prather says that Structure-Function Care can reverse Lung damage and that at Holistic Integration, "We prove it all the time". —The Diathermy treatment used at Holistic Integration that was originally developed for the lungs to treat Pneumonia.  And how patients say they can breathe again after this treatment, which Dr. Prather calls "our magic lung fixer".—The role of allergies and parasites as underlying causes of Asthma.  And how Holistic Integration treats those issues naturally. —How Indianapolis is known as the Histoplasmosis Capitol of the World, which is a cause of Chronic Lower Respiratory Disease.  Plus, how Histoplasmosis is the leading cause of blindness in Indiana. —The most common viruses that cause Chronic Lower Respiratory Disease.  And how COVID helped contribute to lung damage that may lead to more Chronic Lower Respiratory Disease cases in future years.—How cough suppressants prevent mucus from being removed from the body, which is a breeding ground for germs and bacteria.  And how antibiotics will clear up your symptoms, but leave the infection in place to do further damage because they shut the immune response down. —The Importance of Hyaluronic Acid to "re-inflate your lungs" (and also to make your joints feel better).  And the most effective supplement for lung health that Dr. Prather uses at Holistic Integration. http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Before watching the video, can you guess which conditions vitamin D has actually been proven to work for in randomized, double-blind, placebo-controlled trials?

Breathing out shouldn't feel like pushing air through a straw, but for millions of people that's the daily reality of COPD. We sit down and translate chronic obstructive pulmonary disease into plain English, starting with what the name really means and why the main problem is often getting air out, not just getting air in. If you've ever heard someone say they “can't catch their breath,” we give you a clear picture of what may be happening inside the lungs.We walk through a simple model of breathing using an upside-down tree and tiny balloon-like air sacs, then explain what changes in COPD: inflamed, narrowed airways and air sacs that lose their stretch. That combination can trap air, making each new breath feel harder than the last. We also talk about the slow burn of how COPD develops over time, why smoking is the most common cause, and how pollution, occupational dust or chemicals, secondhand smoke, and rare genetic factors can also play a role.From there, we get practical. We cover common COPD symptoms (shortness of breath with activity, chronic cough, mucus, wheezing, fatigue), how spirometry helps diagnose airflow limitation, and what treatment can actually do. We discuss inhalers, pulmonary rehabilitation, oxygen therapy for advanced cases, and why staying up to date on flu, RSV, and COVID vaccines matters for people at higher risk. We also break down COPD exacerbations, the flare-ups often triggered by infections that can cause a step down in lung function, and why early prevention and timely care are so important.Stick around for our post-medicine banter too. If this helped you understand your body a little better, subscribe, share it with someone who needs it, and leave a review so more people can find straightforward health education.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

This week, we begin a four-part series on the 5th-largest killer in America.  In this episode, you'll discover:—How COPD (Chronic Obstructive Pulmonary Disease) is responsible for the overwhelming majority of Chronic Lower Respiratory Disease (or CLRD) deaths.  And how Emphysema and Asthma are also included in this category. —Why Dr. Prather says it is "a major issue" to get patients (and sometimes their doctors) to take their shortness of breath seriously. —The devastating impact of cigarette smoking on CLRD.  And how Dr. Prather has seen young people whose Lungs have shut down even after just three months of vaping.—Why Dr. Prather says that marijuana can actually even be worse than cigarettes on the Lungs.—How Asthma can be a precursor of COPD and damages the Lungs over time.  Plus, the role of obesity in contributing to Lung problems and CLRD. —The influence of nutrition on Lung Disease and why Dr. Prather believes Fiber is the key. —The Alpha-1 antitrypsin generic factor that can be a root cause of Lung disease.  And how infections like Histoplasmosis can increase your risk of developing COPD.—The Spirometry Lung Function Test at Holistic Integration that reveals the health of your Lungs. —How you CAN improve the health of your Lungs and even regenerate your Lungs through Structure-Function Care. —Why Dr. Prather says how deep you breathe is the number one indicator of how long you will live. http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews John Fahy (Division of Pulmonary and Critical Care Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA) about his state-of-the-art review of the pathobiology and treatment of mucus plugs in asthma and COPD , published in this issue of the ERJ (https://doi.org/10.1183/13993003.02358-2025). Cite this podcast as: ERJ Podcast May 2026: Mucus plugs in asthma and COPD. Eur Respir J 2026; 67: 26E6705 [https://doi.org/10.1183/13993003.E6705-2026].

Guest: Barry Quart, CEO and DirectorCompany: Connect Biopharma, NASDAQ:CNTBWebsite: https://www.connectbiopharma.com/Connect Biopharma Bio:Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.Barry Quart Bio:Dr. Barry Quart brings over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. He has personally led several early-stage biotech companies through late-stage clinical development, regulatory strategy, highlighted by nine U.S. Food and Drug Administration (FDA) approved drugs.Dr. Quart was most recently CEO at Heron Therapeutics. He first served as CEO and Director starting 2012, transitioned to President and CEO in 2019 and was named Chair of the Board in October 2020. At Heron, Dr. Quart oversaw the development and approval of four drugs: two drugs for CINV (CINVANTI® and SUSTOL®) and two acute care drugs (ZYNRELEF® and APONVIE®). Prior to Heron, Dr. Quart co-founded Ardea Biosciences, Inc. in 2006 and served as its President and Chief Executive Officer and Director from its inception through its acquisition by AstraZeneca PLC in 2012. At Ardea, Dr. Quart invented and oversaw the development of a drug for gout (ZURAMPIC®), as well as the design and development of a series of MEK inhibitors for cancer that were licensed to Bayer AG. Dr. Quart currently serves on the Board of Directors of Kiniksa Pharmaceuticals. He is an inventor on 18 U.S. patents and an author on 75 publications and abstracts. Dr. Quart received his Pharm.D. from the University of California, San Francisco.

Dr. Daphne Bascom earned a DPhil/PhD in physiological sciences at the University of Oxford, a medical degree at the University of Pittsburgh, and completed fellowship training in microvascular and reconstructive surgery of the head and neck at Oregon Health Sciences University. She has more than two decades of executive leadership across health systems, health technology, and community health. Most recently, she served as Vice President of Population Health at Saint Luke’s Health System in Kansas City. So, how and why did she leave all of that to pursue lifestyle medicine, a “vegetable-forward” way of life, and a completely different kind of care? As we've heard from many of our guests, for Dr. Bascom, it was personal. Between witnessing her mother's long and arduous struggle with COPD and helping her father navigate the healthcare system, she recognized that despite her many years of training, her work as a surgeon, and her leadership, she still wasn't doing the work that got her into medicine in the first place. She wanted to help people be healthy. Period.  That deep calling led her to become the Chief Operating Officer of The Vegan Gym, a global digital health platform dedicated to plant-based performance, healthspan, and longevity. She now hosts the Thrive on Plants podcast and is the Founder of The Longevity Lab. As a lifelong believer in equity and inclusion, Dr. Bascom works hard to ensure that this information is accessible to all people, and much of the education she puts together on these topics is available for free on her YouTube channel, @TheVeganGym.

Diana Johnson joined Tom Katz on Wake Up Tri-Counties for the "Here's to Your Health" series, discussing services at Hammond-Henry Hospital. Spotlighting local healthcare, Diana Johnson, a respiratory therapist with nearly two decades at Hammond Henry Hospital, discussed her pivotal role in the pulmonary function department. She performs pulmonary function tests, which help diagnose breathing issues like asthma, COPD, and chronic coughs, on patients ranging from age six to 100. Symptoms prompting referral include persistent shortness of breath or unexplained coughing, especially active during allergy season and for student athletes. The testing process is thorough, and results are reviewed promptly by a pulmonologist to guide further care. More about these services can be found at hammondhenry.com.

COPD can feel overwhelming when you are trying to memorize symptoms, diagnosis criteria, and treatment strategies all at once.      In this episode, Alex and I walk through a practical COPD review that covers the essentials you need to know for boards, including classic presentations, key differences between chronic bronchitis and emphysema, diagnostic spirometry cutoffs, and the GOLD treatment groups.                               Get full show notes, transcript, and more information here: https://blog.npreviews.com/COPD-review-for-boards              Follow us on Instagram: instagram.com/smnpreviewsofficial

While the gut microbiome often steals the spotlight, the microorganisms residing in our respiratory tract play a vital role in our health and immunity. In this episode, Dr. Sheena Fraser sits down with microbial ecologist Dr. Michael Cox to explore the fascinating, complex, and relatively uncharted territory of the lung microbiome.They discuss how the lung microbiome fundamentally differs from the gut, the daily flux of bacteria entering and leaving our airways, and the profound impacts of environmental factors like air pollution, smoking, vaping, and household cleaning products. Plus, Dr. Cox shares the massive challenges scientists face when studying these deep-tissue microbes and what the future of respiratory medicine might look like.What We Cover:From Seawater to Sputum: Using marine ecology techniques to decode human respiratory biology.Exploring the lungs' dynamic balance of microaspiration and mucociliary clearance.Meet the core lung bacteria (Streptococcus, Prevotella, Veillonella) and the puzzle of anaerobes in an oxygen-rich space.Environmental Disruptors: How pollution, smoking, and vaping inflame and alter the lung microbiome.Hidden Dangers of VOCs: The silent impact of everyday cleaning sprays and aerosols on respiratory health.Diet, Exercise, & Epigenetics: The systemic benefits of a high-fiber diet and fitness for chronic lung conditions like COPD and asthma.About Dr. Michael Cox is a microbial ecologist and the PGR Lead for the Institute of Microbiology and Infection at the University of Birmingham. His research focuses on the bacteria that reside in the respiratory tract in the context of respiratory diseases (such as COPD and Cystic Fibrosis). His lab works to understand the function of the respiratory microbiome, translate these findings for clinical benefit, and expand our understanding of the respiratory ecosystem beyond just bacteria.Connect with Dr Michael Cox:University of BirminghamScientific References & Further Reading:Cumming, K. J. (2018). "Long term effects of cleaning on the lungs." American Journal of Respiratory and Critical Care Medicine, 197(9):1099-1101.Hussain, S., et al. (2024). "Unlocking the secrets: VOCs and their devastating effects on lung cancer." Pathology - Research and Practice, 255:155157.Welsh, H. A., et al. (2026). "The effect of vaping on the human lung microbiota." Inhalation Toxicology, Vol 38, Iss 1.This podcast is brought to you in collaboration with the British Society of Lifestyle Medicine.Disclaimer:The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.

Optimize patient outcomes by selecting the right inhaler device for the right patient. Credit available for this activity expires: 4/30/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/right-fit-personalizing-copd-device-selection-across-patient-2026a1000dcc?ecd=bdc_podcast_libsyn_mscpedu

In this episode of Let's Talk Micro, we continue our gram-negative cocci series with a closer look at Moraxella catarrhalis—better known at the bench as the hockey puck bug. We break down what makes this organism unique, from its classic sliding colony morphology to how it behaves in different patient populations. Is it a colonizer or a pathogen? The answer depends on the clinical context. We walk through its role in pediatric infections like otitis media and sinusitis, its significance in adults—especially in COPD—and how to interpret its presence in respiratory cultures. As always, we tie it back to the bench, discussing identification clues, culture considerations, and what it means when you see this organism on your plate. Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Chronic conditions like obesity, diabetes, COPD, and congestive heart failure are reshaping the U.S. healthcare system — and the demand for durable medical equipment along with it. In this episode of Industry Matters, VGM's Tyler Coulander and Alan Morris dig into the data behind America's growing chronic disease burden, what it means for DME providers navigating the shift from hospital-based to home-based care, and why demand for equipment and long-term patient support is more resilient than ever. They also tackle the big GLP-1 question: do drugs like Ozempic threaten CPAP and diabetes equipment markets, or do they actually open new doors? Tune in for a high-level look at the forces driving industry growth — and check out the VGM Industry Insights library for a deeper dive into the data.Watch the video version on YouTube: https://youtu.be/rwZAg90E3d8

Send us Fan MailPulmonologist Dr. Mitchell Rothstein shares his expertise on chronic obstructive pulmonary disorder, COPD. He explains what the condition is, how it manifests in the body, and the risks of untreated COPD. Dr. Rothstein also reviews available mainstream COPD medications and explains that even with the best medications, a failure in delivery can lower effectiveness. Dr. Rothstein also talks about the role inflammation can play for some people with COPD and discusses new biologic medications that may help lower the burden for many COPD sufferers.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment. With over 30 years in pharmaceutical R&D and nine FDA-approved drugs to his name, Barry shares a rare insider perspective on building and scaling biotech companies—from pioneering HIV therapies that reshaped the AIDS epidemic to leading next-generation biologics targeting acute asthma exacerbations. He unpacks Connect's differentiated IL-4 receptor biology, the untapped opportunity in acute care settings, and why innovation has lagged for decades in treating exacerbations despite millions of ER visits annually. The conversation also explores the realities of running a publicly traded biotech in volatile markets, the evolving role of China in global drug discovery, and how leaders navigate geopolitical complexity while advancing science. As Connect approaches key clinical catalysts, this episode offers a compelling look at where biotech innovation, capital, and global strategy intersect. Biography: Dr. Barry Quart is the CEO of Connect Biopharma, (Nasdaq: CNTB), a clinical-stage company developing therapies for acute exacerbations of inflammatory diseases, such as asthma and COPD. Barry is currently leading the company's development of rademikibart, a best-in-class antibody that targets interleukin-4 receptor alpha (IL-4Rα) and reduces severe flare-ups called “exacerbations” that can occur with asthma and COPD and can lead to hospitalization and even death. Connect is the first company to enter this space addressing acute exacerbations of inflammatory diseases. Dr. Quart is a recognized industry leader with over 30 years of leadership experience and nine FDA-approved drugs under his belt. Barry brings deep expertise in drug development, biotech strategy, and bringing breakthrough therapies to the market. He holds a PharmD from the University of California, San Francisco.

In this episode of Docs in a Pod, hosts Dr. Rajay Seudath and Carmenn Miles sit down with Dr. Rodrigo Pereira for an informative and approachable conversation about Chronic Obstructive Pulmonary Disease (COPD). Together, they break down what COPD is, common causes and symptoms, and why early detection is so important. Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT: 

Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory condition that nurses encounter frequently in both inpatient and outpatient settings. Effective pharmacologic management plays a major role in controlling symptoms, preventing exacerbations, and improving quality of life for patients living with COPD. In this episode, we'll review the key medication classes used to manage COPD and highlight practical clinical considerations nurses should know when caring for these patients. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!